Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 18;10(9):723.
doi: 10.3390/genes10090723.

Thyroid Cancer in the Pediatric Population

Affiliations
Review

Thyroid Cancer in the Pediatric Population

Vera A Paulson et al. Genes (Basel). .

Abstract

Thyroid cancer is rare in the pediatric population, but thyroid carcinomas occurring in children carry a unique set of clinical, pathologic, and molecular characteristics. In comparison to adults, children more often present with aggressive, advanced stage disease. This is at least in part due to the underlying biologic and molecular differences between pediatric and adult thyroid cancer. Specifically, papillary thyroid carcinoma (which accounts for approximately 90% of pediatric thyroid cancer) has a high rate of gene fusions which influence the histologic subtypes encountered in pediatric thyroid tumors, are associated with more extensive extrathyroidal disease, and offer unique options for targeted medical therapies. Differences are also seen in pediatric follicular thyroid cancer, although there are few studies of non-papillary pediatric thyroid tumors published in the literature due to their rarity, and in medullary carcinoma, which is most frequently diagnosed in the pediatric population in the setting of prophylactic thyroidectomies for known multiple endocrine neoplasia syndromes. The overall shift in the spectrum of histotypes and underlying molecular alterations common in pediatric thyroid cancer is important to recognize as it may directly influence diagnostic test selection and therapeutic recommendations.

Keywords: gene rearrangements; molecular testing; pediatric thyroid cancer; targeted cancer therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

Cited by

References

    1. Howlader N., Noone A.M., Krapcho M., Miller D., Brest A., Yu M., Ruhl J., Tatalovich Z., Mariotto A., Lewis D.R., et al., editors. SEER Cancer Statistics Review, 1975–2016. National Cancer Institute; Bethesda, MD, USA: 2019.
    1. Bernier M.O., Withrow D.R., Berrington de Gonzalez A., Lam C.J.K., Linet M.S., Kitahara C.M., Shiels M.S. Trends in pediatric thyroid cancer incidence in the United States, 1998–2013. Cancer. 2019 doi: 10.1002/cncr.32125. - DOI - PMC - PubMed
    1. Qian Z.J., Jin M.C., Meister K.D., Megwalu U.C. Pediatric Thyroid Cancer Incidence and Mortality Trends in the United States, 1973–2013. JAMA Otolaryngol. Head Neck Surg. 2019 doi: 10.1001/jamaoto.2019.0898. - DOI - PMC - PubMed
    1. Mon R., Newlon J. Anaplastic carcinoma of the thyroid in a 12-year old girl. J. Pediatr. Surg. Case Rep. 2015;3:404–406. doi: 10.1016/j.epsc.2015.08.004. - DOI
    1. Wu Y.L., Ting W.H., Wey S.L., Chen C.K., Huang C.Y., Cheng S.P., Lees Y.J. Poorly differentiated thyroid carcinoma in a 9-year-old boy: Case report. J. Pediatr. Endocrinol. Metab. 2011;24:783–786. doi: 10.1515/JPEM.2011.209. - DOI - PubMed